Nymox Pharmaceutical Corporation EPS Ratio 2011-2026 | NYMX

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Nymox Pharmaceutical Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-0.15	-0.16	-0.19	-0.18	-0.26	-0.28	-0.48	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-0.15	-0.48	-0.243

Quarterly EPS Ratio Nymox Pharmaceutical Corporation

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-0.03	-	-0.06	-0.04	-0.04	-	-0.04	-0.08	-0.04	-	-0.05	-0.04	-0.05	-	-0.09	-0.05	-0.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-0.03	-0.09	-0.0515

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
AbbVie ABBV	1.02	$ 208.84	-2.86 %	$ 369 B	USA
AbCellera Biologics ABCL	-0.49	$ 3.52	0.28 %	$ 1.05 B	Canada
Grifols, S.A. GRFS	0.28	$ 8.24	-0.12 %	$ 6.83 B	Spain
Ascendis Pharma A/S ASND	-8.28	$ 229.25	0.44 %	$ 5 B	Danmark
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Genfit SA GNFT	1.51	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
ANI Pharmaceuticals ANIP	-1.04	$ 74.21	-2.3 %	$ 1.43 B	USA
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	-1.08	$ 1.41	2.17 %	$ 375 M	Britain
AgeX Therapeutics AGE	-1.91	-	-10.17 %	$ 12.2 K	USA
Cocrystal Pharma COCP	-0.78	$ 1.51	48.04 %	$ 17 M	USA
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
AIkido Pharma AIKI	-1.57	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Allena Pharmaceuticals ALNA	-0.72	-	3.16 %	$ 1.9 M	USA
BioMarin Pharmaceutical BMRN	1.82	$ 55.5	-3.04 %	$ 10.6 B	USA
Alpine Immune Sciences ALPN	-1.73	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-1.96	-	10.36 %	$ 9.8 M	USA
Arcturus Therapeutics Holdings ARCT	-2.4	$ 8.03	2.29 %	$ 220 M	Israel
Adaptive Biotechnologies Corporation ADPT	-0.39	$ 14.81	2.63 %	$ 2.25 B	USA
Altimmune ALT	-1	$ 3.34	7.05 %	$ 294 M	USA
BioNTech SE BNTX	42.2	$ 91.18	1.97 %	$ 27.2 B	Germany
Amgen AMGN	14.3	$ 347.94	-1.51 %	$ 187 B	USA
Aurinia Pharmaceuticals AUPH	1.6	$ 15.61	0.9 %	$ 2.1 B	Canada
Bristol-Myers Squibb Company BMY	3.47	$ 59.6	-2.45 %	$ 121 B	USA
Aptose Biosciences APTO	-10.4	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-0.96	-	-39.0 %	$ 4.57 M	USA
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
Burford Capital Limited BUR	75.3	$ 4.14	-2.59 %	$ 683 M	Britain
BioCryst Pharmaceuticals BCRX	-0.43	$ 9.02	-3.84 %	$ 1.86 B	USA
Avenue Therapeutics ATXI	-0.93	-	-52.27 %	$ 4.45 M	USA
Atea Pharmaceuticals AVIR	-1.94	$ 5.76	1.95 %	$ 469 M	USA
BeiGene, Ltd. BGNE	0.2	-	0.49 %	$ 251 B	Cayman-islands
AVROBIO AVRO	0.27	-	1083.1 %	$ 745 M	USA
Cellectis S.A. CLLS	-2.55	$ 3.41	1.19 %	$ 116 M	France
Biogen BIIB	8.83	$ 177.34	-3.5 %	$ 26 B	USA
Axcella Health AXLA	-1.49	-	-16.42 %	$ 249 M	USA
Axon Enterprise AXON	4.98	$ 412.81	-2.54 %	$ 31.3 B	USA